Stephen MacMillan - Hologic Chairman, CEO and Pres
| HOLX Stock | USD 79.50 0.06 0.08% |
Chairman
Mr. Stephen P. MacMillan is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. MacMillan was appointed as President, Chief Executive Officer and a director in December 2013 and was elected Chairman of the Board in June 2015. From October 2012 to December 2013, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, a biomedical research company. From 2003 to 2012, he served in various roles at Stryker Corporationrationration, including Chief Operating Officer from 2003 to 2005, Chief Executive Officer from 2005 to 2012 and Chairman from 2010 to 2012. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporationrationration, where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson Johnson in a variety of senior roles in both the U.S. and Europe, including as President of its consumer pharmaceuticals joint venture with Merck. Mr. MacMillan began his career with Procter Gamble in 1985. Mr. MacMillan currently serves on the Board of Trustees of Davidson College since 2015.
| Age | 60 |
| Tenure | 9 years |
| Address | 250 Campus Drive, Marlborough, MA, United States, 01752 |
| Phone | 508 263 2900 |
| Web | https://www.hologic.com |
Stephen MacMillan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen MacMillan against Hologic stock is an integral part of due diligence when investing in Hologic. Stephen MacMillan insider activity provides valuable insight into whether Hologic is net buyers or sellers over its current business cycle. Note, Hologic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hologic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen MacMillan over six months ago Disposition of 12000 shares by Stephen MacMillan of Hologic subject to Rule 16b-3 |
Hologic Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1385 %, meaning that it created $0.1385 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.09 in 2024. Return On Capital Employed is likely to drop to 0.08 in 2024. At this time, Hologic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 4 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.1 B in 2024.Similar Executives
| Found 14 records | CHAIRMAN Age | ||
| Michael Ball | Alcon AG | 69 | |
| Richard Meelia | Haemonetics | 71 | |
| Allan Rubenstein | The Cooper Companies, | 74 | |
| Vincent Forlenza | Becton Dickinson and | 66 | |
| George Fotiades | AptarGroup | 67 | |
| Patrick Zenner | West Pharmaceutical Services | 73 | |
| Vivek Jain | ICU Medical | 52 | |
| Ronald Gelbman | Haemonetics | 70 | |
| Liam Kelly | Teleflex Incorporated | 57 | |
| Fred Lampropoulos | Merit Medical Systems | 74 | |
| Peter Farrell | ResMed Inc | 78 | |
| D Grossman | Alcon AG | 60 | |
| Thomas Polen | Becton Dickinson and | 51 | |
| Ellen Zane | Haemonetics | 69 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0645 |
Hologic Leadership Team
Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Malenchini, Chief Officer | ||
| Peter Dunne, Senior Resources | ||
| Benjamin Cohn, Principal Chief Accounting Officer | ||
| Erik Anderson, Division Solutions | ||
| Mark Irving, VP Secretary | ||
| Stephen MacMillan, Chairman, CEO and Pres | ||
| Kevin Thornal, Group Solutions | ||
| Karleen CPA, Chief Officer | ||
| Scott Christensen, Quality Chain | ||
| John JD, General Counsel | ||
| Elisabeth Hellmann, Sr Communications | ||
| John Griffin, General Counsel | ||
| Jennifer Schneiders, President Solutions | ||
| Mike Kelly, Chief Affairs | ||
| Essex Mitchell, Chief Officer | ||
| Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada | ||
| Ryan Simon, Vice Relations | ||
| Karleen Oberton, CFO, Chief Accounting Officer | ||
| Monica Berthelot, VP Staff | ||
| Diana SPHR, Senior Resources | ||
| Brandon Schnittker, Division Solutions |
Hologic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0645 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 18.35 B | ||||
| Shares Outstanding | 226.94 M | ||||
| Shares Owned By Insiders | 0.78 % | ||||
| Shares Owned By Institutions | 99.22 % | ||||
| Number Of Shares Shorted | 4.59 M | ||||
| Price To Earning | 10.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hologic Stock Analysis
When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.